New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapies. On the latest BioCentury This Week podcast, BioCentury’s analysts review the most promising targets and trends shaping the Parkinson’s treatment landscape. The team then turns to AstraZeneca’s build-out of its obesity portfolio, followed by FDA’s Operation TrialBlazer and what the reforms mean for reducing the time to launch a clinical trial i...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from BioCentury This Week
Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard
Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data
Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson
Ep. 376 - M&A momentum: 3Q public markets preview
Get summaries like this every morning.
Free AI-powered recaps of BioCentury This Week and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.